Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 2, 2003, Pages 363-369

  Zarrindast, Mohammad Reza ^a   Faraji, Nasrin ^b   Rostami, Parvin ^c   Sahraei, Hedayat ^d   Ghoshouni, Hassan ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c KHARAZMI UNIVERSITY   (Iran)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Conditioned place preference; Mecamylamine; Morphine; Naloxone; Nicotine; Tolerance

Indexed keywords

MECAMYLAMINE; MORPHINE; NALOXONE; NICOTINE; NARCOTIC AGENT; NARCOTIC ANTAGONIST; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; AVERSION; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG CROSS TOLERANCE; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; ANIMAL; DRUG ANTAGONISM; DRUG TOLERANCE; INSTRUMENTAL CONDITIONING;

ANIMALS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; MECAMYLAMINE; MICE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RECEPTORS, OPIOID;

EID: 0037213128     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)01002-X     Document Type: Article

References (34)

1. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome and self-administrative behavior. Pharmacol. Rev. 46:1994;293-324.
2. Calabresi P., Lacey M.G., North R.A. Nicotine excitation of rat ventral tegmental area neurones in vitro studied by intracellular recording. Br. J. Pharmacol. 98:1989;135-140.
3. Calcagnetti D.J., Schechter M.D. Nicotine place preference using the biased method of conditioning. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;925-933.
4. Carr G.D., White N.M. Conditioned place preference from intra-accumbens but not intra-caudate amphetamine injections. Life Sci. 33:1983;2551-2557.
5. Corrigall W.A., Herling S., Coen K.M. Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacology (Berlin). 96(1):1988;29-35.
6. Davenport K.E., Houdi A.A., Van Lon G.R. Nicotine protects against μ-opioid receptor antagonism by β-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113:1990;40-46.
7. Di Chiara G. Role of dopamine in the behavioral actions of nicotine related to addiction. Eur. J. Pharmacol. 393(1-3):2000;295-314.
8. Di Chiara G., Imperato A. Drugs abused by humans preferentially induce synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
9. Eiden L.E., Giraud P., Dave J.R., Hotchkiss A.J., Affolter H.U. Nicotinic receptor stimulation activates enkephalin release and biosynthesis in adrenal chromaffin cell. Nature. 312:1984;661-663.
10. Gossop M., Powell J., Grey S., Hajek P. What do opiate addicts and cigarette smokers mean by "craving"? A pilot study. Drug Alcohol Depend. 26:1990;85-87.
11. Houdi A.A., Pierzchala K., Marson L., Palkovits M., Van Loon G.R. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides. 12:1991;161-166.
12. Ismail Z., el-Guebaly N. Nicotine and endogenous opioids: toward specific pharmacotherapy. Can. J. Psychiatry. 43:1998;37-42.
13. Kest B., Lee C.E., Mc Lemore G.L., Inturrisi C.E. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res. Bull. 39:1996;185-188.
14. Kivastik T., Rutkauskaite J., Zharkovsky A. Nitric oxide synthesis inhibition attenuates morphine-induced place preference. Pharmacol. Biochem. Behav. 53:1996;1013-1015.
15. Koob G.F. Drugs of abuse: anatomy, pharmacology, and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
16. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 24:2001;97-129.
17. Marks M.J., Burch J.A., Collins A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J. Pharmacol. Exp. Ther. 236:1983;817-825.
18. Martin B.R., Onaivi E.S., Martin T.J. What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem. Pharmacol. 38:1989;3391-3397.
19. Nisell M., Nomikos G.G., Svensson T.H. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol. Toxicol. 75:1994;348-352.
20. Olmstead M.C., Franklin K.B.J. The development of a conditioned place preference to morphine: effects of microinjections into various CNS sites. Behav. Neurosci. 111:1997;1324-1334.
21. Pauly J.R., Grun E.U., Collins A.C. Tolerance to nicotine following chronic treatment by injections: a potential role for corticosterone. Psychopharmacology. 108:1992;33-39.
22. Pomerleau O.F. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology. 23:1998;115-130.
23. Rezayat M., Nikfar S., Zarrindast M.R. CCK receptor activation may prevent tolerance to morphine in mice. Eur. J. Pharmacol. 254:1994;21-26.
24. Rodriguez De Fonseca F., Rubio P., Martin-Calderon J.L., Caine S.B., Koob G.F., Navarro M. The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. Eur. J. Pharmacol. 274:1995;47-55.
25. Rosecrans J.A., Hendry J.S., Hong J.S. Biphasic effects of chronic nicotine treatment on hypothalamic immunoreactive beta-endorphin in the mouse. Pharmacol. Biochem. Behav. 23:1985;141-143.
26. Sanchez-Blazquez P., Rodriguez M.D., Garzon J. Antibodies directed against the mu-opioid receptor alleviated multiple signs of morphine withdrawal in mice. Life Sci. 59:1996;PL87-PL92.
27. Shoaib M., Stolerman I.P., Kumar R.C. Nicotine-induced place preferences following prior nicotine exposure in rats. Psychopharmacology. 113:1994;445-452.
28. Susuki T. Blockade of morphine-induced place preference by diazepam in mice. Eur. J. Pharmacol. 280:1995;327-330.
29. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 56:1998;613-672.
30. Wang Z., Bilsky E.J., Porreca F., Sadee W. Constitutive μ-opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci. 54:1994;PL339-PL350.
31. Watkins S.S., Koob G.F., Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob. Res. 2:2000;19-37.
32. Zarrindast M.R., Farzin D. Nicotine attenuates naloxone-induced jumping behaviour in morphine dependent mice. Eur. J. Pharmacol. 298:1996;1-6.
33. Zarrindast M.R., Khoshayand M.R., Shafaghi B. The development of cross-tolerance between morphine and nicotine in mice. Eur. J. Neuropsychopharmacol. 9:1999;227-233.
34. Zarrindast M.R., Barghi-Lashkari S., Shafizadeh M. The possible cross-tolerance between morphine- and nicotine-induced hypothermia in mice. Pharmacol. Biochem. Behav. 68:2001;283-289.